anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
### 

Adverse Events from Ankylosing Spondylitis Studies: A total of 378 patients were treated with CELEBREX in placebo- and active-controlled AS studies. Doses up to 400 mg once daily were studied. The types of adverse events reported in the AS studies were similar to those reported in the OA/RAstudies.

### 

Adverse Events from Analgesia and Dysmenorrhea Studies: Approximately 1,700 patients were treated with CELEBREX in analgesia and dysmenorrhea studies. All patients in post-oral surgery pain studies received a single dose of study medication. Doses up to 600 mg/day of CELEBREX were studied in primary dysmenorrhea and post-orthopedic surgery pain studies. The types of adverse events in the analgesia and dysmenorrhea studies were similar to those reported in arthritis studies. The only additional adverse event reported was post-dental extraction alveolar osteitis (dry socket) in the post-oral surgery pain studies.

### 

Adverse Events from the Familial Adenomatous Polyposis Study: The adverse event profile reported for the 83 patients with familial adenomatous polyposis enrolled in the randomized, controlled clinical trial was similar to that reported for patients in the arthritis-controlled trials. Intestinal anastomotic ulceration was the only new adverse event reported in the FAP trial, regardless of causality, and was observed in 3 of 58 patients (one at 100 mg twice daily, and two at 400 mg twice daily) who had prior intestinal surgery.
OBJECTIVES: Overactivity is a characteristic of individuals with chronic pain. Previous cross-sectional studies demonstrated a relationship between perfectionism and overactivity. Therefore, the present study used a longitudinal design to determine whether pain severity and pain interference were exacerbated by overactivity and whether overactivity was exacerbated by perfectionism.
METHODS: Participants with chronic pain were recruited using crowdsourcing. The participants completed the questionnaires at three time points: T1, T2, and T3 (September, October, and November 2021, respectively). The questionnaire assessed overactivity, perfectionistic strivings, perfectionistic concerns, pain severity, and pain interference. We created cross-lagged panel models to examine the hypothesized relationships among pain, overactivity, and perfectionism.
RESULTS: After excluding ineligible participants and invalid response sets, we analyzed the questionnaires completed by 666 participants at T1, 560 at T2, and 554 at T3. The average duration of chronic pain at T1 was 36.35 ± 53.53 months. Perfectionistic strivings were partially linked to overactivity, and pain interference was partially related to overactivity. Contrary to our expectations, overactivity did not predict pain severity or pain interference.
CONCLUSIONS: The hypotheses that perfectionism exacerbates overactivity and that overactivity exacerbates pain severity and pain interference were not supported. These results may have been affected by the quality of the assessment of overactivity. Therefore, further research with a refined evaluation of overactivity is required.
Participants will generate positive recent past events that have happened to them at several time points in the previous day (e.g., 7pm-10pm, 4pm-7pm, 1pm-4pm, 10am-1pm, and 7am-10am). During Sham LIFU, the device will be set up identically as in real LIFU. However, the device will be turned off.
Sixty patients AC who applied to our Orthopedics-Traumatology and Physical Medicine-Rehabilitation Outpatient Clinic were included in our study. The study was approved by the Hitit University Clinical Research Ethics Committee (Decision number:2023-56). A well-informed written consent was obtained from all participants according to the principles of the Declaration of Helsinki. Patients with an age range of 18-65 years, adapting to the treatment program to be applied, diagnosed with unilateral stage 2-3 AC, no shoulder trauma in the last 3 months, no shoulder injections, no bleeding disorder, no history of malignancy, inflammatory disease and stroke were included in the study. The patients were randomized into two groups according to the sealed envelope method. In the evaluation of the patients before the injection, age, gender, body mass index (BMI), occupation, education, duration of complaint, symptomatic side and dominant hand information were recorded. Injections were made to the patients by the physiatrist and anesthetist researcher under the guidance of Logiq V2 portable USG device. In the first group, 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine injection were mixed with the posterior approach method into the shoulder joint under the guidance of USG. The second group underwent suprascapular nerve block injection with 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine under USG guidance. In addition, pendulum and ladder-finger exercises were given to both groups as a home exercise program. Shoulder range of motion (ROM), visual analog scale (VAS) scores and Shoulder Pain and Disability Index (SPADI) scores were compared before the injection, on the tenth day after the injection and at the third month after the injection.
INTRODUCTION: Temporal data has numerous challenges for deep learning such as irregularity of sampling. New algorithms are being developed that can handle these temporal challenges better. However, it is unclear how the performance ranges from classical non-temporal models to newly developed algorithms. Therefore, this study compares different non-temporal and temporal algorithms for a relevant use case, the prediction of atrial fibrillation (AF) using general practitioner (GP) data.
METHODS: Three datasets with a 365-day observation window and prediction windows of 14, 180 and 360 days were used. Data consisted of medication, lab, symptom, and chronic diseases codings registered by the GP. The benchmark discarded temporality and used logistic regression, XGBoost models and neural networks on the presence of codings over the whole year. Pattern data extracted common patterns of GP codings and tested using the same algorithms. LSTM and CKConv models were trained as models incorporating temporality.
RESULTS: Algorithms which incorporated temporality (LSTM and CKConv, (max AUC 0.734 at 360 days prediction window) outperformed both benchmark and pattern algorithms (max AUC 0.723, with a significant improvement using the 360 days prediction window (p = 0.04). The difference between the benchmark and the LSTM or CKConv algorithm decreased with smaller prediction windows, indicating temporal importance for longer prediction windows. The CKConv and LSTM algorithm performed similarly, possibly due to limited sequence length.
CONCLUSION: Temporal models outperformed non-temporal models for the prediction of AF. For temporal models, CKConv is a promising algorithm to handle temporal data using GP data as it can handle irregular data.
BACKGROUND: We aimed to investigate the efficacy of shoulder hydrodilatation (HD) applied in addition to suprascapular nerve blockage (SSNB) on severity of pain, shoulder joint range of motion (ROM), functional status, handgrip (HG) strength in patients with adhesive capsulitis (AC).
METHODS: Forty-eight patients who were diagnosed with AC based on physical examination findings included in the study. The patients were randomized into two groups as combination of SSNB + HD and SSNB alone. Injections were performed under ultrasonography guidance. Shoulder ROM angles were measured with a goniometer. Pain intensity was evaluated with visual analog scale. Functional status was evaluated with Quick Disability of Arm, Shoulder, and Hand (QDASH). HG strength was measured by a Jamar dynometer. After the injection, a home-based exercise program was given to all patients. Patients were evaluated at baseline, 1st and 3rd month.
RESULTS: Abduction and external rotation ROM angles were statistically significantly limited in SSNB group, at baseline (p = 0.020, p = 0.018, respectively). In terms of other parameters, both groups were similar at baseline (p > 0.05). At comparison of baseline-1st month, a significant improvement was observed in VAS score, abduction and flexion ROM and QDASH score, in both groups (p < 0.05), however, there was no statistically significant difference between the groups. There is a statistically significant decrease in VAS score in both groups, at all times, but, no significant difference between the groups. At the comparison of baseline-3rd month measurements, it was observed that all of the parameters significantly improved in both groups, and there was no statistically significant difference between the groups except for abduction and external rotation ROM (p > 0.05). Abduction ROM and external rotation ROM were significantly higher in the SSNB group than SSNB + HD group at 3rd month.
CONCLUSIONS: Both SSNB + HD and SSNB alone provide significant improvement clinically especially in shoulder pain. HD added to SSNB does not seem to provide any additional benefit. SSNB is an effective treatment option for up to 3 months in patients with AC, mainly in abduction and external rotation limitation.
The present invention relates to an siRNA delivery system in which siRNA and mesoporous silica nanoparticles are combined by a divalent metal cation. In addition, the present invention relates to a preparation method of the siRNA delivery system and a pharmaceutical composition for treating cancer including the siRNA delivery system. The siRNA delivery system according to the present invention is capable of loading siRNA onto MSN without conventional amine functionalization, by using divalent metal cations such as biologically safe calcium ions and the like. The siRNA delivery system of the present invention exhibits excellent biocompatibility, and is capable of stably delivering siRNA into cells. In addition, a gene and a drug can be simultaneously delivered by carrying an additional drug in pores, and the siRNA can be used as a pharmaceutical composition for cancer treatment. The siRNA of the present invention can be simply prepared as a raw port by simply mixing siRNA, mesoporous silica nanoparticles, and salt of divalent metal cations. Furthermore, the siRNA delivery system of the present invention can be extended with respect to a wide range of silica particles having various properties in terms of pore and particle sizes, surface composition, and the like. The present invention may provide a novel type of siRNA delivery system and a preparation method thereof.
The invention relates to a compound treating diabetes and relevant complicating diseases and preparation method and application thereof. The invention provides the compound expressed as the formula X:The invention relates to a compound treating diabetes and relevant complicating diseases and preparation method and application thereof. The invention provides the compound expressed as the formula X: shown as the right, wherein R is -OH or R1COO<->, R1 is C2-C20 carbon chain. The invention also provides the method for preparing the compound and a drug compound containing the compound shown as theshown as the right, wherein R is -OH or R1COO<->, R1 is C2-C20 carbon chain. The invention also provides the method for preparing the compound and a drug compound containing the compound shown as theformula X. The invention also provides the application of the compound on preparing medicaments for treating diabetes and relevant complicating diseases. formula X. The invention also provides the application of the compound on preparing medicaments for treating diabetes and relevant complicating diseases.
In the breast milk odor stimulation group, one or two drops of breast milk were placed on a sponge in accordance with the literature. Breast milk was obtained from each infant's own mother by hand expressing. The mothers were asked to express two drops of breast milk from their breasts onto the sponge. The sponge on which the breast milk was dripped was placed as close to the baby's nose as possible without touching the baby's nose. Since breast milk odor stimulation is recommended to be given to the baby for 1 minute in the literature, the baby was allowed to smell the odor of breast milk for 1 minute. The baby was then given to the mother for breastfeeding and breastfeeding was initiated as in routine practice.
AIM: Total mesorectal excision with adequate free margins is the gold standard for rectal surgery. Applying a linear stapler in a narrow pelvis can be challenging and the proper distal margin difficult to assess. In selected cases the colorectal eversion technique combined with single-stapled double-purse-string anastomosis (SSDP) can be a practical solution.
METHOD: Eleven patients, six men and five women, mean body mass index 27 ± 1.3 kg/m2, underwent total mesorectal excision with the colorectal eversion technique combined with modified SSDP between September 2022 and January 2023.
RESULTS: The mean operative time was 190 min. The mean hospital stay was 4 days. There were no postoperative complications. The final histology showed complete mesorectal resection, circumferential resection margin negative, free distal resection margin, anastomotic doughnuts negative. At 7 ± 3 months follow-up there was no evidence of local recurrence or distant metastasis.
CONCLUSION: The colorectal eversion technique combined with modified SSDP is a reproducible and safe technique in selected patients. Prospective randomized trials with large patient series are needed to confirm our preliminary results.
A highly immunoreactive viral peptide, pE2, is disclosed which is derived form the carboxy-terminal end region of ORF2 region of the hepatitis E virus (HEV) genome. A unique feature of the novel pE2 peptide is that it possesses conformational antigenic determinants which are only exposed when monomers of the peptide associate with one another through non-covalent interactions to naturally form homodimers. The novel pE2 peptide is proven to be highly reactive with sera from patients having current or past infection with HEV which suggests that the homodimer may mimic certain structural features of the HEV capsid protein. Furthermore, the antigenic activity of the pE2 peptide is strictly conformational in nature and therefore, exhibits immunochemical reactivity only when the peptide exists in a dimeric form. Consequently, the antigenic activity is lost upon dissociation of the dimers, but the activity is restored when the monomers reassociate to form dimers. Moreover, diagnostic methods useful in detecting and diagnosing HEV infection, and the use of a vaccine composition effective in preventing hepatitis E virus infection in which the novel pE2 peptide is utilized are also disclosed.
This study utilizes a randomized control study design. According to the situated learning theory and qualitative research findings, this study develops a board game. This study enrolled adolescents with Tourette syndrome aged 12 to 18 as the subjects. Participants played board games at home at least once (about 60 minutes) a week for four consecutive weeks. The control group received the usual standard of care (psychoeducation regarding Tourette Syndrome and one 50-mg tablet of pyridoxine daily). The effectiveness indicators include self-reported status of positive mental health, tics severity, social adjustment, and depression by adolescents with TS.
PURPOSE: A cosmetic composition containing an extract of Myxobacterium cultures is provided to suppress tyrosinase activity and to ensure antioxidation, skin whitening, and/or anti-aging effects. CONSTITUTION: A cosmetic composition contains 0.00001-20 wt% of an extract of Myxobacterium cultures. The cosmetic composition ensures antioxidation or suppresses tyrosinase activity. Myxobacterium includes Corallococcus coralloides, Myxococcus sp., or Sorangium cellulosum. The Myxobacterium is Corallococcus coralloides KCTC 11967BP. A cosmetic product contains the cosmetic composition and is manufactured in the form of a skin softener, a lotion, a nutrition cream, a massage cream, an essence, a pack, an emulsion, or oil gel.
Improvements in surgical techniques, perioperative management and effective chemotherapy regimens, have increased the resectability of malignant hepatobiliary and pancreatic tumors when associated with vascular invasion. Therefore, simultaneous vascular resection is increasingly required to obtain an adequate resection margin and improve patient definite survival. Although most vascular resection associated with pancreatectomy can be reconstructed by simple venorraphy or end-to-end anastomosis, a segmental or lateral vacular graft (VG) can be necessary in 8-12 % of cases. Vascular reconstruction can be planned preoperatively if the vascular invasion is evident and an appropriate VG can be prepared. Differents sources of VG are available including autogenous veins , synthetic such as polytetrafluoroethylene (PTFE) , cryopreserved and veins from the resected liver. However the decision to perform vascular resection may be made during dissection due to vascular invasion or injury and even occasionnally taken while the mesentericoportal vein (MPV) or vena cava (VC) are occluded. In this emergency situation, an urgent and easily available graft is necessary to prevent prolonged ischemia. The difficulty of anticipating the need for these vascular resections during HPB surgery, has lead certain authors including those in our group to use either the veins from the resected liver, the umbilical vein or the parietal peritoneum (PP) for vena cava reconstruction. The aim of our study is to evaluate the safety and outcome of the parietal peritoneum as a substitute patch for venous reconstruction during HPB surgery in emergency and elective situations.
The invention relates to a process for producing a uterine contraction medicament which uses carbetocin as a main drug. The process comprises a synthesis process and a preparation process. The technical scheme of solid-phase synthesis comprises the following steps of: 1, carrying out deprotection by using amino resin as a vector; 2, connecting carboxyl of Fmoc-Gly-OH with amino of the resin to obtain Fmoc-Gly-amino resin; 3, carrying out solid-phase synthesis sequentially to form sequence residual protection amino acid; 4, removing side-chain protecting groups of cysteine; 5, connecting brombutyl acid onto sulfydryl of cysteine; 6, removing terminal amino Fmoc protection; 7, carrying out solid-phase cyclization; 8, cutting to obtain carbetocin crude peptides; and 9, refining to obtain a carbetocin pure product. The process has the characteristics of simple reaction operation, easy post treatment, high yield, low cost and the like. The invention also discloses a process for preparing a carbetocin freeze-dried powder injection which mainly comprises the following material compositions: carbetocin serving as the main drug, an excipient, a pH (potential of hydrogen) value regulator and water for injection. The powder injection has the advantages of high dispersion degree, high stability and the like.
On March 11, 2020, a global pandemic was declared by the World Health Organization. A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of the COVID-19 pandemic. SARS-CoV-2 infection has quickly become one of the fastest growing and deadliest diseases to surface due to its high death rate and ability to replicate and spread readily from people without symptoms. Recent evidence indicates that critically ill patients with COVID-19 experience a high risk of blood clots. Deep leg vein blood clots can travel to the lungs and cause severe lung failure and death. The geko™ device is a simple device that increases the return of blood flow from the lower legs and potentially decrease the risk of lung blood clots. Investigators believe the geko™ device may have an important benefit in COVID-19 patients by decreasing the risk of lung clots and decrease the risk of respiratory failure which is often the cause of death in COVID-19 patients. In this study, Investigators plan to study the effect of using the geko™ device in COVID-19 patients and measure patient outcomes such as ICU admission and death. The findings of this study have the potential to decrease the complications seen in COVID-19 infections.
This study will examine whether new processed and technologies for monitoring diabetic patients' insulin levels improves patient care. Patients at Brigham and Women's Hospital (BWH), staying on the General Medicine Service, who have Type 2 diabetes and who are not on IV insulin can participate in this study. Physicians and nurses will be taught new rules to care for diabetic patients, while in the hospital. Also, the BWH computer system will be updated to include these new rules for administering insulin. Patients who participate in the study will be randomly placed into one of two groups: one group that will be cared for by physicians and nurses who have learned these new rules for administering insulin; or the second group, who will receive diabetes care at BWH before the new rules were adopted. The study will last approximately 1 year.
Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Screening assays are provided for identifying compounds, preferably organic compounds, preferably aromatic and heterocylic sulfonamides, which inhibit the enzymatic activity of MN/CA IX and that are useful for treating patients with preneoplastic/neoplastic disease. Further, the CA IX-specific inhibitors when labeled or linked to an appropriate visualizing means can also be used diagnostically/prognostically for preneoplastic/neoplastic disease, and for imaging use, for example, to detect hypoxic precancerous cells, tumors and/or metastases, by selectively binding to activated CA IX, preferably CA IX activated under hypoxic conditions, and not to inactive CA IX. Such detection of hypoxic conditions can be helpful in determining effective treatment options, and in predicting treatment outcome and the prognosis of disease development. Still further, the CA IX-specific inhibitors can be used therapeutically to selectively target hypoxic cells expressing activated CA IX. The CA IX-specific inhibitors can be labelled or conjugated to radioisotopes for radiotherapy of hypoxic cells. Alternatively, the CA IX-specific inhibitors can be used for gene therapy coupled to vectors for targeted delivery to hypoxic preneoplastic/neoplastic cells expressing activated CA IX on their surfaces. 
     In an alternative mode of the invention, CA IX-specific inhibitors may be used therapeutically to target acidic conditions of a tumor, e.g., to increase pHe in order to enhance the efficacy of weak base chemotherapeutic drugs.